Search

Your search keyword '"Callejas J"' showing total 195 results
Start Over Author "Callejas J"
195 results on '"Callejas J"'

1. POS1007 THE INVOLVEMENT OF THE C5 AND C5AR1 GENES IN THE PATHOGENESIS OF IgAV

Author

Batista-Liz, J. C., primary, Calvo-Río, V., additional, Sebastián Mora-Gil, M., additional, Sevilla-Pérez, B., additional, Callejas, J. L., additional, Leonardo, M. T., additional, Peñalba, A., additional, Cabero, M. J., additional, Narváez, J., additional, Martín-Penagos, L., additional, Belmar-Vega, L., additional, Gomez-Fernandez, C., additional, Caminal-Montero, L., additional, Collado, P., additional, Quiroga Colina, P., additional, Vicente-Rabaneda, E., additional, Rubio-Romero, E., additional, León Luque, M., additional, Blanco-Madrigal, J. M., additional, Galíndez-Agirregoikoa, E., additional, Castañeda, S., additional, Blanco, R., additional, Pulito-Cueto, V., additional, and López-Mejías, R., additional

Published
2024
Full Text
View/download PDF

2. AB1240 NLRP3 AND CASP1 GENES AS DISCRIMINATORY MARKERS BETWEEN IGA VASCULITIS AND IGA NEPHROPATHY?

Author

Batista-Liz, J. C., primary, Sebastián Mora-Gil, M., additional, Gabrie, L., additional, Gálvez-Sánchez, R., additional, Leonardo, M. T., additional, Peñalba, A., additional, Sevilla-Pérez, B., additional, Callejas, J. L., additional, Caminal-Montero, L., additional, Narváez, J., additional, Martín-Penagos, L., additional, Belmar-Vega, L., additional, Collado, P., additional, Fernández-Nebro, A., additional, Díaz-Cordoves, G., additional, Quiroga Colina, P., additional, Vicente-Rabaneda, E., additional, Cigarrán, S., additional, Calviño, J., additional, Cobelo, C., additional, Rubio-Romero, E., additional, León Luque, M., additional, Blanco-Madrigal, J. M., additional, Galíndez-Agirregoikoa, E., additional, Castañeda, S., additional, Blanco, R., additional, Pulito-Cueto, V., additional, and López-Mejías, R., additional

Published
2024
Full Text
View/download PDF

3. OP0133 INVESTIGATING THE GENETIC BACKGROUND OF THE SEX DIMORPHISM IN SYSTEMIC SCLEROSIS

Author

Rodriguez-Martin, I., primary, Kerick, M., additional, Rosa-Baez, C., additional, Borrego-Yaniz, G., additional, Ortiz-Fernández, L., additional, Guillen-Del-Castillo, A., additional, Simeón-Aznar, C. P., additional, Callejas, J. L., additional, Assassi, S., additional, Ssc Group, I., additional, Proudman, S. M., additional, Nikpour, M., additional, Interest Group (Asig), A. S., additional, Hunzelmann, N., additional, Moroncini, G., additional, De Vries-Bouwstra, J. K., additional, Orozco, G., additional, Barton, A., additional, Herrick, A. L., additional, Allanore, Y., additional, Fonseca, C., additional, Beretta, L., additional, Denton, C. P., additional, Mayes, M. D., additional, Martin, J., additional, and Acosta-Herrera, M., additional

Published
2024
Full Text
View/download PDF

4. POS0256 THE FIRST METHYLOME PROFILING STUDY OF B-CELLS IN IGA VASCULITIS REVEALED POTENTIAL BIOMARKERS OF DISEASE SUSCEPTIBILITY

Author

López-Mejías, R., primary, Pulito-Cueto, V., additional, Fernández Rengel, I., additional, Terron Camero, L. C., additional, Batista-Liz, J., additional, Sebastián Mora-Gil, M., additional, Leonardo, M. T., additional, Peñalba, A., additional, Martín-Penagos, L., additional, Belmar-Vega, L., additional, Gomez-Fernandez, C., additional, Gabrie, L., additional, Gálvez-Sánchez, R., additional, Caminal-Montero, L., additional, Turrión, A. I., additional, Quiroga Colina, P., additional, Vicente-Rabaneda, E., additional, Sevilla-Pérez, B., additional, Callejas, J. L., additional, Andrés-León, E., additional, Martin, J., additional, Márquez, A., additional, Castañeda, S., additional, and Blanco, R., additional

Published
2024
Full Text
View/download PDF

5. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group

Author

Sánchez-Cano, D., Ortego-Centeno, N., Callejas, J. L., Fonollosa Plá, V., Ríos-Fernández, R., Tolosa-Vilella, C., Espinosa-Garriga, G., Colunga-Argüelles, D., Egurbide-Arberas, M. V., Rubio-Rivas, M., Freire, M., Ríos-Blanco, J. J., Trapiella-Martínez, L., Rodríguez-Carballeira, M., Marín-Ballvé, A., Pla-Salas, X., and Simeón-Aznar, C. P.

Published
2018
Full Text
View/download PDF

7. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

Author

Kerick, M, Acosta-Herrera, M, Pilar Simeon-Aznar, C, Luis Callejas, J, Assassi, S, Proudman, SM, Nikpour, M, Hunzelmann, N, Moroncini, G, de Vries-Bouwstra, JK, Orozco, G, Barton, A, Herrick, AL, Terao, C, Allanore, Y, Fonseca, C, Eugenia Alarcon-Riquelme, M, Radstake, TRDJ, Beretta, L, Denton, CP, Mayes, MD, Martin, J, Kerick, M, Acosta-Herrera, M, Pilar Simeon-Aznar, C, Luis Callejas, J, Assassi, S, Proudman, SM, Nikpour, M, Hunzelmann, N, Moroncini, G, de Vries-Bouwstra, JK, Orozco, G, Barton, A, Herrick, AL, Terao, C, Allanore, Y, Fonseca, C, Eugenia Alarcon-Riquelme, M, Radstake, TRDJ, Beretta, L, Denton, CP, Mayes, MD, and Martin, J

Abstract

Copy number (CN) polymorphisms of complement C4 play distinct roles in many conditions, including immune-mediated diseases. We investigated the association of C4 CN with systemic sclerosis (SSc) risk. Imputed total C4, C4A, C4B, and HERV-K CN were analyzed in 26,633 individuals and validated in an independent cohort. Our results showed that higher C4 CN confers protection to SSc, and deviations from CN parity of C4A and C4B augmented risk. The protection contributed per copy of C4A and C4B differed by sex. Stronger protection was afforded by C4A in men and by C4B in women. C4 CN correlated well with its gene expression and serum protein levels, and less C4 was detected for both in SSc patients. Conditioned analysis suggests that C4 genetics strongly contributes to the SSc association within the major histocompatibility complex locus and highlights classical alleles and amino acid variants of HLA-DRB1 and HLA-DPB1 as C4-independent signals.

Published
2022

8. Study of association of CTLA4 gene variants to non-anterior uveitis

Author

Rodriguez, Leon D. A., Lopera, Serrano A., Cordero-Coma, M., Márquez, A., Fonollosa, A., Ruiz-Arruza, I., Callejas, J. L., Serrano, García J. L., Valle, Díaz D., Pato, E., Cañal, J., del Rio, M. J., Capella, M. J., Blanco, A., Olea, J. L., Cordero, Y., Martín-Villa, J. M., Gorroño-Echebarría, M. B., Molins, B., Adán, A., and Martin, J.

Published
2015
Full Text
View/download PDF

9. Effectiveness of Tocilizumab in Cranial and Extracranial Phenotypes of Giant Cell Arteritis: Multicenter Study of 471 Cases

Author

Sanchez-Bilbao L, Loricera J, Castaneda S, Moriano C, Narvaez J, Aldasoro V, Maiz O, Melero R, Villa J, Vela P, Romero-Yuste S, Callejas J, De Miguel E, Galindez-Agirregoikoa E, Sivera F, Fernandez-Lopez J, Galisteo C, Ferraz-Amaro I, Nieto J, de Dios J, Sanchez J, Fernandez E, de la Morena I, Moya P, Solans-Laque R, Andreu J, Revenga M, Labrador E, Garcia-Valle A, Gallego A, Iniguez C, Hidalgo C, Garrido-Punal N, Lopez-Gonzalez R, Roman-Ivorra J, Arija S, Collado P, Raya E, Navarro F, Mas A, Ordas C, Boquet M, Alvarez-Rivas N, Velloso-Feijoo M, Campos-Fernandez C, Rua-Figueroa I, Conesa A, Salgado E, Gonzalez-Gay M, and Blanco R

Published
2021

10. Effectiveness of Tocilizumab in the Visual Involvement of Giant Cell Arteritis: Multicenter Study of 471 Patients of Clinical Practice

Author

Sanchez-Bilbao L, Loricera J, Acha J, Moriano C, Narvaez J, Aldasoro V, Maiz O, Melero R, Villa J, Vela P, Romero-Yuste S, Callejas J, De Miguel E, Galindez-Agirregoikoa E, Sivera F, Fernandez-Lopez J, Galisteo C, Ferraz-Amaro I, Nieto J, de Dios J, Sanchez J, Fernandez E, de la Morena I, Moya P, Solans-Laque R, Andreu J, Revenga M, Pinillos V, Garcia-Valle A, Gallego A, Iniguez C, Hidalgo C, Garrido-Punal N, Lopez-Gonzalez R, Roman-Ivorra J, Arija S, Collado P, Raya E, Navarro F, Mas A, Ordas C, Boquet M, Alvarez-Rivas N, Velloso-Feijoo M, Campos-Fernandez C, Rua-Figueroa I, Conesa A, Salgado E, Gonzalez-Gay M, and Blanco R

Published
2021

11. SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients

Author

Brito-Zerón, Pilar, Melchor, Sheila, Seror, Raphaèle, Priori, Roberta, Solans, Roser, Kostov, Belchin, Baldini, Chiara, Carubbi, Francesco, Callejas, Jose Luis, Guisado-Vasco, Pablo, Hernández-Molina, Gabriela, Pasoto, Sandra G, Valim, Valeria, Sisó-Almirall, Antoni, Mariette, Xavier, Carreira, Patricia, Ramos-Casals, Manuel, Brito-Zerón, P, Morcillo, C, Flores-Chávez, A, Ramos-Casals, M, Acar-Denizli, N, Horvath, I F, Szanto, A, Tarr, T, Seror, R, Mariette, X, Mandl, T, Olsson, P, Li, X, Xu, B, Baldini, C, Bombardieri, S, Gottenberg, J E, Gandolfo, S, De Vita, S, Priori, R, Giardina, F, Hernandez-Molina, G, Sánchez-Guerrero, J, Kruize, A A, Hinrichs, A, Valim, V, Isenberg, D, Solans, R, Rischmueller, M, Downie-Doyle, S, Kwok, S-K, Park, S-H, Nordmark, G, Suzuki, Y, Kawano, M, Giacomelli, R, Devauchelle-Pensec, V, Saraux, A, Hofauer, B, Knopf, A, Bootsma, H, Vissink, A, Morel, J, Vollenveider, C, Atzeni, F, Retamozo, S, Moça Trevisano, V, Armagan, B, Kilic, L, Kalyoncu, U, Pasoto, S G, Kostov, B, Sisó-Almirall, A, Consani-Fernández, S, Carubbi, F, Callejas, J L, López-Dupla, M, Pérez-Alvarez, R, Akasbi, M, Guisado-Vasco, P, Sánchez, I, Hospital Universitario 12 de Octubre [Madrid], EULAR standing committee of People with Arthritis/Rheumatism in Europe (PARE), H. CIMA-Sanitas, Barcelona, CELLEX-IDIBAPS Department of Autoimmune Diseases, Barcelona, Instituto Mexicano del Seguro Social [Mexico City, Mexico] (IMSS), Universidad de Colima [Mexico], Hospital Clinic [Barcelona, Spain], İstanbul Üniversitesi, İstanbul, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary, MTA-Debreceni Egyetem, Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Center for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre, Skåne University Hospital [Malmö, Suède], Stockholm University, Wuhan University [China], Pisa University Hospital, Nuclear Medicine Unit, Humanitas Gavazzeni, Bergamo, Italy, University Hospitals, Strasbourg, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán - National Institute of Medical Science and Nutrition Salvador Zubiran [Mexico], Federal University of Espírito Santo, University Hospital Vall d’Hebròn [Barcelona, Spain], Lymphocytes B, Autoimmunité et Immunothérapies (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-LabEX IGO Immunothérapie Grand Ouest, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut d'Investigaciones Biomèdiques August Pi i Sunye (IDIBAPS), Università degli studi di Palermo - University of Palermo, Hospitales Universitarios de Granada/Universidad de Granada, Hospital Universitario Quironsalud, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Rheumatology Unit, Department of Internal Medicine, University of Palermo, Palermo, Italy, and Michel, Geneviève

Subjects
Male, medicine.medical_specialty, Multivariate analysis, [SDV.IMM] Life Sciences [q-bio]/Immunology, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Comorbidity, Laboratory abnormality, comorbidities, outcomes, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Risk Factors, Internal medicine, medicine, Humans, In patient, Pharmacology (medical), 030212 general & internal medicine, Registries, Risk factor, Primary Sjögren Syndrome, AcademicSubjects/MED00360, ComputingMilieux_MISCELLANEOUS, 030203 arthritis & rheumatology, business.industry, SARS-CoV-2, COVID-19, Primary SS, SARS-Cov-2, Middle Aged, medicine.disease, 3. Good health, Hospitalization, Sjogren's Syndrome, [SDV.IMM]Life Sciences [q-bio]/Immunology, Original Article, Female, business
Abstract

Objective To analyse the prognosis and outcomes of SARS-CoV-2 infection in patients with primary SS. Methods We searched for patients with primary SS presenting with SARS-CoV-2 infection (defined following and according to the European Centre for Disease Prevention and Control guidelines) among those included in the Big Data Sjögren Registry, an international, multicentre registry of patients diagnosed according to the 2002/2016 classification criteria. Results A total of 51 patients were included in the study (46 women, mean age at diagnosis of infection of 60 years). According to the number of patients with primary SS evaluated in the Registry (n = 8211), the estimated frequency of SARS-CoV-2 infection was 0.62% (95% CI 0.44, 0.80). All but two presented with symptoms suggestive of COVID-19, including fever (82%), cough (57%), dyspnoea (39%), fatigue/myalgias (27%) and diarrhoea (24%), and the most frequent abnormalities included raised lactate dehydrogenase (LDH) (88%), CRP (81%) and D-dimer (82%) values, and lymphopenia (70%). Infection was managed at home in 26 (51%) cases and 25 (49%) required hospitalization (five required admission to ICU, four died). Compared with patients managed at home, those requiring hospitalization had higher odds of having lymphopenia as laboratory abnormality (adjusted OR 21.22, 95% CI 2.39, 524.09). Patients with comorbidities had an older age (adjusted OR 1.05, 95% CI 1.00, 1.11) and showed a risk for hospital admission six times higher than those without (adjusted OR 6.01, 95% CI 1.72, 23.51) in the multivariate analysis. Conclusion Baseline comorbidities were a key risk factor for a more complicated COVID-19 in patients with primary SS, with higher rates of hospitalization and poor outcomes in comparison with patients without comorbidities.

Published
2020

12. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort

Author

Namjou, B, Kothari, P H, Kelly, J A, Glenn, S B, Ojwang, J O, Adler, A, Alarcón-Riquelme, M E, Gallant, C J, Boackle, S A, Criswell, L A, Kimberly, R P, Brown, E, Edberg, J, Stevens, A M, Jacob, C O, Tsao, B P, Gilkeson, G S, Kamen, D L, Merrill, J T, Petri, M, Goldman, R R, Vila, L M, Anaya, J-M, Niewold, T B, Martin, J, Pons-Estel, B A, Sabio, J M, Callejas, J L, Vyse, T J, Bae, S-C, Perrino, F W, Freedman, B I, Scofield, R H, Moser, K L, Gaffney, P M, James, J A, Langefeld, C D, Kaufman, K M, Harley, J B, and Atkinson, J P

Published
2011
Full Text
View/download PDF

18. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

Author

Lopez-Isac, Elena, Acosta-Herrera, Marialbert, Kerick, Martin, Assassi, Shervin, Satpathy, Ansuman T., Granja, Jeffrey, Mumbach, Maxwell R., Beretta, Lorenzo, Simeon, Carmen P., Carreira, Patricia, Ortego-Centeno, Norberto, Castellvi, Ivan, Bossini-Castillo, Lara, David Carmona, F., Orozco, Gisela, Hunzelmann, Nicolas, Distler, Joerg H. W., Franke, Andre, Lunardi, Claudio, Moroncini, Gianluca, Gabrielli, Armando, de Vries-Bouwstra, Jeska, Wijmenga, Cisca, Koeleman, Bobby P. C., Nordin, Annika, Padyukov, Leonid, Hoffmann-Vold, Anna-Maria, Lie, Benedicte, Rios, R., Callejas, J. L., Vargas-Hitos, J. A., Garcia-Portales, R., Camps, M. T., Fernandez-Nebro, A., Gonzalez-Escribano, M. F., Garcia-Hernandez, F. J., Castillo, M. J., Aguirre, M. A., Gomez-Gracia, I., Fernandez-Gutierrez, B., Rodriguez-Rodriguez, L., Garcia de la Pena, P., Vicente, E., Andreu, J. L., Fernandez de Castro, M., Lopez-Longo, F. J., Martinez, L., Fonollosa, V, Guillen, A., Espinosa, G., Tolosa, C., Pros, A., Rodriguez-Carballeira, M., Narvaez, F. J., Rubio-Rivas, M., Ortiz-Santamaria, V, Madronero, A. B., Gonzalez-Gay, M. A., Diaz, B., Trapiella, L., Sousa, A., Egurbide, M. V., Fanlo-Mateo, P., Saez-Comet, L., Diaz, F., Hernandez, V, Beltran, E., Roman-Ivorra, J. A., Grau, E., Alegre-Sancho, J. J., Freire, M., Blanco-Garcia, F. J., Oreiro, N., Witte, T., Kreuter, A., Riemekasten, G., Airo, P., Magro, C., Voskuyl, A. E., Vonk, M. C., Hesselstrand, R., Proudman, Susanna, Stevens, Wendy, Nikpour, Mandana, Zochling, J., Sahhar, J., Roddy, J., Nash, P., Tymms, K., Rischmueller, M., Lester, S., Vyse, Timothy, Herrick, Ariane L., Worthington, Jane, Denton, Christopher P., Allanore, Yannick, Brown, Matthew A., Radstake, Timothy R. D. J., Fonseca, Carmen, Chang, Howard Y., Mayes, Maureen D., Martin, Javier, Lopez-Isac, Elena, Acosta-Herrera, Marialbert, Kerick, Martin, Assassi, Shervin, Satpathy, Ansuman T., Granja, Jeffrey, Mumbach, Maxwell R., Beretta, Lorenzo, Simeon, Carmen P., Carreira, Patricia, Ortego-Centeno, Norberto, Castellvi, Ivan, Bossini-Castillo, Lara, David Carmona, F., Orozco, Gisela, Hunzelmann, Nicolas, Distler, Joerg H. W., Franke, Andre, Lunardi, Claudio, Moroncini, Gianluca, Gabrielli, Armando, de Vries-Bouwstra, Jeska, Wijmenga, Cisca, Koeleman, Bobby P. C., Nordin, Annika, Padyukov, Leonid, Hoffmann-Vold, Anna-Maria, Lie, Benedicte, Rios, R., Callejas, J. L., Vargas-Hitos, J. A., Garcia-Portales, R., Camps, M. T., Fernandez-Nebro, A., Gonzalez-Escribano, M. F., Garcia-Hernandez, F. J., Castillo, M. J., Aguirre, M. A., Gomez-Gracia, I., Fernandez-Gutierrez, B., Rodriguez-Rodriguez, L., Garcia de la Pena, P., Vicente, E., Andreu, J. L., Fernandez de Castro, M., Lopez-Longo, F. J., Martinez, L., Fonollosa, V, Guillen, A., Espinosa, G., Tolosa, C., Pros, A., Rodriguez-Carballeira, M., Narvaez, F. J., Rubio-Rivas, M., Ortiz-Santamaria, V, Madronero, A. B., Gonzalez-Gay, M. A., Diaz, B., Trapiella, L., Sousa, A., Egurbide, M. V., Fanlo-Mateo, P., Saez-Comet, L., Diaz, F., Hernandez, V, Beltran, E., Roman-Ivorra, J. A., Grau, E., Alegre-Sancho, J. J., Freire, M., Blanco-Garcia, F. J., Oreiro, N., Witte, T., Kreuter, A., Riemekasten, G., Airo, P., Magro, C., Voskuyl, A. E., Vonk, M. C., Hesselstrand, R., Proudman, Susanna, Stevens, Wendy, Nikpour, Mandana, Zochling, J., Sahhar, J., Roddy, J., Nash, P., Tymms, K., Rischmueller, M., Lester, S., Vyse, Timothy, Herrick, Ariane L., Worthington, Jane, Denton, Christopher P., Allanore, Yannick, Brown, Matthew A., Radstake, Timothy R. D. J., Fonseca, Carmen, Chang, Howard Y., Mayes, Maureen D., and Martin, Javier

Abstract

Systemic sclerosis (SSc) is an autoimmune disease that shows one of the highest mortality rates among rheumatic diseases. We perform a large genome-wide association study (GWAS), and meta-analysis with previous GWASs, in 26,679 individuals and identify 27 independent genome-wide associated signals, including 13 new risk loci. The novel associations nearly double the number of genome-wide hits reported for SSc thus far. We define 95% credible sets of less than 5 likely causal variants in 12 loci. Additionally, we identify specific SSc subtype-associated signals. Functional analysis of high-priority variants shows the potential function of SSc signals, with the identification of 43 robust target genes through HiChIP. Our results point towards molecular pathways potentially involved in vasculopathy and fibrosis, two main hallmarks in SSc, and highlight the spectrum of critical cell types for the disease. This work supports a better understanding of the genetic basis of SSc and provides directions for future functional experiments.

Published
2019

19. First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort

Author

Ruiz-Irastorza, G., Garcia, M., Espinosa, G., Caminal, L., Mitjavila, F., Gonzalez-Leon, R., Sopena, B., Canora, J., Villalba, M. V., Rodriguez-Carballeira, M., Lopez-Dupla, J. M., Callejas, J. L., Castro, A., Tolosa, C., Sanchez-Garcia, M. E., Perez-Conesa, M., Navarrete-Navarrete, N., Rodriguez, A. P., Herranz, M. T., Pallares, L., RELES, Autoimmune Dis Study Grp GEAS, [Ruiz-Irastorza, G.] Univ Basque Country, Autoimmune Dis Res Unit, Dept Internal Med, BioCruces Hlth Res Inst,Hosp Univ Cruces, Baracaldo, Bizkaia, Spain, [Garcia, M.] Univ Basque Country, Autoimmune Dis Res Unit, Dept Internal Med, BioCruces Hlth Res Inst,Hosp Univ Cruces, Baracaldo, Bizkaia, Spain, [Espinosa, G.] Hosp Clin Barcelona, Dept Autoimmune Dis, Barcelona, Spain, [Caminal, L.] Hosp Univ Cent Asturias, Dept Internal Med, Oviedo, Asturias, Spain, [Mitjavila, F.] Hosp Univ Bellvitge, Dept Internal Med, Autoimmune Dis Unit, Barcelona, Spain, [Gonzalez-Leon, R.] Hosp Univ Virgen del Rocio, Dept Internal Med, Seville, Spain, [Sopena, B.] Complejo Hosp Univ Vigo, Dept Internal Med, Vigo, Spain, [Canora, J.] Hosp Univ Fuenlabrada, Dept Internal Med, Madrid, Spain, [Villalba, M. V.] Hosp Gen Univ Gregorio Maranon, Dept Internal Med, Madrid, Spain, [Rodriguez-Carballeira, M.] Hosp Univ Mutua Terrasa, Dept Internal Med, Barcelona, Spain, [Lopez-Dupla, J. M.] Hosp Univ Joan XXIII, Dept Internal Med, Tarragona, Spain, [Callejas, J. L.] Hosp Univ San Cecilio, Dept Internal Med, Granada, Spain, [Castro, A.] Hosp Univ St Joan de Reus, Dept Internal Med, Tarragona, Spain, [Tolosa, C.] Corporacio Sanitaria Parc Tauli, Dept Internal Med, Barcelona, Spain, [Sanchez-Garcia, M. E.] Hosp Univ Reina Sofia, Dept Internal Med, Autoimmune Dis Unit, Cordoba, Spain, [Perez-Conesa, M.] Hosp Univ Miguel Servet, Dept Internal Med, Zaragoza, Spain, [Navarrete-Navarrete, N.] Hosp Univ Virgen de las Nieves, Dept Internal Med, Granada, Spain, [Rodriguez, A. P.] Complejo Hosp Univ Ourense, Dept Internal Med, Orense, Spain, [Herranz, M. T.] Hosp JM Morales Meseguer, Dept Internal Med, Murcia, Spain, [Pallares, L.] Hosp Univ Son Espases, Dept Internal Med, Islas Baleares, Spain, Spanish Society of Internal Medicine, RELES, Autoimmune Diseases Study Group (GEAS), [Ruiz-Irastorza,G, Garcia,M] Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Bizkaia, Spain. [Espinosa,G] Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain. [Caminal,L] Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Asturias , Spain. [Mitjavila,F] Autoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. [González-León,R] Department of Internal Medicine , Hospital Universitario Virgen del Rocío, Sevilla, Spain. [Sopeña,B] Department of Internal Medicine, Complejo Hospitalario Universitario de Vigo, Pontevedra, Vigo , Spain. [Canora,J] Department of Internal Medicine, Hospital Universitario Fuenlabrada, Fuenlabrada, Madrid , Spain. [Villalba,MV] Department of Internal Medicine, Hospital General Universitario Gregorio Marañón, Madrid, Spain. [Rodríguez-Carballeira,M] Department of Internal Medicine, Hospital Universitario Mutua de Terrasa, Barcelona, Spain. [López-Dupla,JM] Department of Internal Medicine, Hospital Universitario Joan XXIII, Tarragona, Spain. [Callejas,JL] Department of Internal Medicine, Hospital Universitario San Cecilio, Granada, Spain. [Castro,A] Department of Internal Medicine, Hospital Universitario Sant Joan de Reus, Reus, Tarragona , Spain. [Tolosa,C] Department of Internal Medicine, Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain. [Sánchez-García,ME] Department of Internal Medicine, Autoimmune Diseases Unit, Hospital Universitario Reina Sofía , Córdoba, Spain. [Pérez-Conesa,M] Department of Internal Medicine, Hospital Universitario Miguel Servet, Zaragoza, Spain. [Navarrete-Navarrete,N] Department of Internal Medicine , Hospital Universitario Virgen de las Nieves, Granada, Spain. [Rodríguez,AP] Department of Internal Medicine, Complejo Hospitalario Universitario de Ourense, Ourense, Spain. [Herranz,MT] Department of Internal Medicine, Hospital J.M. Morales Meseguer, Murcia, Spain. [Pallarés,L] Department of Internal Medicine, Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain., and This study was supported by the Spanish Society of Internal Medicine.

Subjects
0301 basic medicine, Lupus nephritis, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, immune system diseases, Prednisone, Nefritis lúpica, Phenomena and Processes::Circulatory and Respiratory Physiological Phenomena::Cardiovascular Physiological Phenomena::Hemodynamics::Pulse [Medical Subject Headings], skin and connective tissue diseases, Diseases::Skin and Connective Tissue Diseases::Connective Tissue Diseases::Lupus Erythematosus, Cutaneous::Lupus Erythematosus, Discoid [Medical Subject Headings], Systemic lupus erythematosus, Lupus eritematoso discoide, Cumulative dose, General Medicine, Humanos, Chemicals and Drugs::Polycyclic Compounds::Steroids::Pregnanes::Pregnadienes::Pregnadienetriols::Prednisolone::Methylprednisolone [Medical Subject Headings], Cohort, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors::Immunosuppressive Agents [Medical Subject Headings], Glucocorticoid, medicine.drug, medicine.medical_specialty, Antimaláricos, Immunology, Diseases::Skin and Connective Tissue Diseases::Connective Tissue Diseases::Lupus Erythematosus, Systemic::Lupus Nephritis [Medical Subject Headings], Brief Communication, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiparasitic Agents::Antiprotozoal Agents::Antimalarials [Medical Subject Headings], Systemic Lupus Erythematosus, Disease activity, 03 medical and health sciences, Internal medicine, Lupus eritematoso sistémico, medicine, Corticosteroids, Metilprednisolona, Glucocorticoides, Disease Activity, 030203 arthritis & rheumatology, business.industry, Diseases::Skin and Connective Tissue Diseases::Connective Tissue Diseases::Lupus Erythematosus, Systemic [Medical Subject Headings], Inmunosupresores, Pulso arterial, medicine.disease, Chemicals and Drugs::Polycyclic Compounds::Steroids::Pregnanes::Pregnadienes::Pregnadienediols::Prednisone [Medical Subject Headings], Chemicals and Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Adrenal Cortex Hormones::Glucocorticoids [Medical Subject Headings], 030104 developmental biology, Endocrinology, Prednisona, Observational study, business
Abstract

Aim: To study the influence of prednisone dose during the first month after systemic lupus erythematosus (SLE) diagnosis (prednisone-1) on glucocorticoid burden during the subsequent 11 months (prednisone-2-12). Methods: 223 patients from the Registro Espanol de Lupus Eritematoso Sisternico inception cohort were studied. The cumulative dose of prednisone-1 and prednisone-2-12 were calculated and recoded into a four-level categorical variable: no prednisone, low dose (up to 7.5 mg/day), medium dose (up to 30 mg/day) and high dose (over 30 mg/day). The association between the cumulative prednisone-1 and prednisone-2-12 doses was tested. We analysed whether the four level prednisone-1 categorical variable was an independent predictor of an average dose >7.5 mg/day of prednisone-2-12. Adjusting variables included age, immunosuppressives, antimalarials, methyl-prednisolone pulses, lupus nephritis and baseline SLE Disease Activity Index (SLEDAI). Results: Within the first month, 113 patients (51%) did not receive any prednisone, 24 patients (11%) received average low doses, 46 patients (21%) received medium doses and 40 patients (18%) received high doses. There was a strong association between prednisone-1 and prednisone-2-12 dose categories (p7.5 mg/day, while patients receiving low dose prednisone-1 were not (adjusted OR 1.4, 95% CI 0. 0.38 to 5.2). If the analysis was restricted to the 158 patients with a baseline SLEDAI of >= 6, the model did not change. Conclusion: The dose of prednisone during the first month after the diagnosis of SLE is an independent predictor of prednisone burden during the following 11 months., This study was supported by the Spanish Society of Internal Medicine.

Published
2016

20. Estudio CRONO: prevalencia del dolor irruptivo en pacientes con dolor crónico no oncológico en Andalucía, España

Author

Rodríguez-López, M. J., Torres Morera, Luis Miguel, Herrera Silva, J., Velázquez Rivera, I., Caballero-Callejas, J., Heredia-Gil, F. J., González Mesa, J.M., Sánchez del Águila, M. J., Santiago-Martín, J., Rodríguez-Rodríguez, C., Collazo Chao, Eliseo, Alba-Moreno, R. de, Jiménez-López, A. J., Gálvez Mateos, Rafael, Neira Reina, Fernando, Bustos-Rivera, A., Gallego, J., Rodríguez-López, M. J., Torres Morera, Luis Miguel, Herrera Silva, J., Velázquez Rivera, I., Caballero-Callejas, J., Heredia-Gil, F. J., González Mesa, J.M., Sánchez del Águila, M. J., Santiago-Martín, J., Rodríguez-Rodríguez, C., Collazo Chao, Eliseo, Alba-Moreno, R. de, Jiménez-López, A. J., Gálvez Mateos, Rafael, Neira Reina, Fernando, Bustos-Rivera, A., and Gallego, J.

Abstract

Objective: The aim of this study was to evaluate the prevalence of breakthrough pain (BTP) in ambulatory patients with non-cancer chronic pain in Spain and to characterize physiopathology, location, intensity and frequency of BTP episodes. Methods: Prospective, non-interventional, observational study conducted in 16 pain units of hospitals of Andalusia and Ceuta. Eligible consecutive patients were are asked if they experience BTP defined as "a transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite stable and controlled background pain". At each survey day, the first two patients reporting BTP were further interrogated on the clinical characteristics of their BTP (etiology, onset, intensity, frequency and treatment). Results: A total of 3,209 patients with non-cancer chronic pain were screened to identify 1,118 patients with BTP, which represented a prevalence of 36 %. BTP characteristics were retrieved from 350 patients: mean BTP intensity was 8.3 (± 1.4) on a Visual Analogue Scale (VAS), with a mean of 2 episodes/24 hour (range 1-5/24 h). Pain mechanism was mixed in 149 (42.6 %), neuropathic in 91 (26 %) and nociceptive in 72 in (20.6 %) of patients. Significant correlation was found between BTP intensity and both higher background pain (r = 0.243, p < 0.001), and daily BTP episodes frequency (r = 0.123, p = 0.003). 78 % of the patients were on opioid treatment. The most frequent were fentanyl citrate (52.6 %) and tramadol (17.4 %). Conclusions: The prevalence rate of BTP in patients with chronic non-oncologic pain is higher than one-third of the patients seen in outpatient hospital pain units in Spain. BTP causes reduced levels of functionality, psychological disorders, and an increase in health care expenditure. Individualization is the key to treatment., RESUMEN Objetivo: El objetivo de este estudio es evaluar la prevalencia de dolor irruptivo (DI) en pacientes ambulatorios con dolor crónico de origen no oncológico y caracterizar la fisiopatología, localización, intensidad y frecuencia de los episodios de DI. Material y métodos: Estudio observacional, prospectivo y no intervencionista realizado en 16 unidades de dolor ambulatorias de hospitales de Andalucía y Ceuta. Se preguntó a los pacientes consecutivos elegibles si experimentan DI definido como "una exacerbación transitoria del dolor que ocurre espontáneamente, o en relación con un desencadenante predecible o impredecible específico, a pesar del dolor de base estable y controlado". En cada día de la encuesta, los dos primeros pacientes que confirmaron DI fueron preguntados sobre las características clínicas de su PTP (etiología, inicio, intensidad, frecuencia y tratamiento). Resultados: Se realizó un cribaje a un total de 3209 pacientes con dolor crónico no oncológico para identificar a 1118 pacientes con DI, lo que representó una prevalencia del 36 %. Se obtuvieron las características del DI de 350 pacientes: la intensidad media fue de 8,3 (± 1,4) en una Escala Analógica Visual (EVA), con una media de 2 episodios/24 horas (rango 1-5/24 h). El mecanismo del dolor fue mixto en 149 (42,6 %), neuropático en 91 (26 %) y nociceptivo en 72 (20,6 %) de los pacientes. Se encontró correlación positiva entre una mayor intensidad de DI con el nivel de dolor basal (r = 0,243, p < 0,001), y el número de crisis diarias de DI (r = 0,123, p = 0,003), ambas estadísticamente significativas. El 78 % de los pacientes estaba en tratamiento con opioides. Los más frecuentes fueron el citrato de fentanilo (52,6 %) y el tramadol (17,4 %). Conclusiones: La tasa de prevalencia del DI en pacientes con dolor crónico no oncológico es superior a un tercio de los pacientes atendidos en las unidades ambulatorias de dolor hospitalario en España. El DI provoca niveles reducidos de funcionalidad

Published
2018

21. Th-2 signature in chronic airway diseases: towards the extinction of asthma-COPD overlap syndrome?

Author

Cosío BG, Pérez de Llano L, Lopez Viña A, Torrego A, Lopez-Campos JL, Soriano JB, Martinez Moragon E, Izquierdo JL, Bobolea I, Callejas J, Plaza V, Miravitlles M, and Soler-Cataluña JJ

Abstract

We aimed to describe the differences and similarities between patients with chronic obstructive airway disease classified on the basis of classical diagnostic labels (asthma, chronic obstructive pulmonary disease (COPD), or asthma-COPD overlap (ACOS)) or according to the underlying inflammatory pattern (Th-2 signature, either Th-2-high or Th-2-low). We performed a cross-sectional study of patients aged >= 40 years and with a post-bronchodilator forced expiratory volume in 1 s to forced vital capacity ratio = 300 cells.mu L-1 and/or a sputum eosinophil count >= 3%. Overall, 292 patients were included in the study: 89 with COPD, 94 NSA and 109 with ACOS (44 SA and 65 with COPD-e). No differences in symptoms or exacerbation rate were found between the three groups. With regards the underlying inflammatory pattern, 94 patients (32.2%) were characterised as Th2- high and 198 (67.8%) as Th-2-low. The Th-2 signature was found in 49% of NSA, 3.3% of patients with COPD, 30% of SA and 49.3% of patients with COPD-e. This classification yielded significant differences in demographic, functional and inflammatory characteristics. We conclude that a classification based upon the inflammatory profile, irrespective of the taxonomy, provides a more clear distinction of patients with chronic obstructive airway disease.

Published
2017

22. FRI0607 Long-term and optimization of infliximab in refractory uveitis associated to behÇet disease. multicentre study of 100 patients

Author

Casas, LC Domínguez, primary, Calvo-Río, V, additional, Beltrán, E, additional, S-Bursόn, J, additional, Mesquida, M, additional, Adán, A, additional, Hernandez, M, additional, L-Longo, F, additional, H-Grafella, M, additional, Valls, E, additional, M-Costa, L, additional, Sellas, A, additional, G-Serrano, J, additional, Callejas, J, additional, Ortego, N, additional, Herreras, J, additional, Follonosa, A, additional, Maíz, O, additional, Blanco, A, additional, Torre, I, additional, F-Espartero, C, additional, Jovani, V, additional, Peitado, D, additional, Díaz-Valle, D, additional, Pato, E, additional, F-Cid, C, additional, Aurrecoechea, E, additional, García, M, additional, Caracuel, M, additional, Atanes, A, additional, Francisco, F, additional, Insua, S, additional, González-Suárez, S, additional, S-Andrade, A, additional, Linares, L, additional, Romero, F, additional, García, A, additional, Almodovar, R, additional, Minguez, E, additional, Carrasco, C, additional, Raya, E, additional, Alcalde, M, additional, F-Carballido, C, additional, Pagés, F, additional, González-Vela, M, additional, Fernández-Díaz, C, additional, Vegas-Revenga, N, additional, Demetrio-Pablo, R, additional, González-Gay, M, additional, and Blanco, R, additional

Published
2017
Full Text
View/download PDF

23. First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort

Author

Ruiz-Irastorza, G, primary, Garcia, M, additional, Espinosa, G, additional, Caminal, L, additional, Mitjavila, F, additional, González-León, R, additional, Sopeña, B, additional, Canora, J, additional, Villalba, M V, additional, Rodríguez-Carballeira, M, additional, López-Dupla, J M, additional, Callejas, J L, additional, Castro, A, additional, Tolosa, C, additional, Sánchez-García, M E, additional, Pérez-Conesa, M, additional, Navarrete-Navarrete, N, additional, Rodríguez, A P, additional, Herranz, M T, additional, and Pallarés, L, additional

Published
2016
Full Text
View/download PDF

24. Electrokinetic Analysis of the Influence of Additives on Calcium Oxalate Crystallization

Author

Callejas, J.; Biocolloids and Fluid Physics Group, Department of Applied Physics, University of Granada, 18071 Granada, Martinez, R.; Biocolloids and Fluid Physics Group, Department of Applied Physics, University of Granada, 18071 Granada, De Las Nieves, F. J.; Biocolloids and Fluid Physics Group, Department of Applied Physics, University of Granada, 18071 Granada, Hidalgo-Alvarez, R.; Biocolloids and Fluid Physics Group, Department of Applied Physics, University of Granada, 18071 Granada, Callejas, J.; Biocolloids and Fluid Physics Group, Department of Applied Physics, University of Granada, 18071 Granada, Martinez, R.; Biocolloids and Fluid Physics Group, Department of Applied Physics, University of Granada, 18071 Granada, De Las Nieves, F. J.; Biocolloids and Fluid Physics Group, Department of Applied Physics, University of Granada, 18071 Granada, and Hidalgo-Alvarez, R.; Biocolloids and Fluid Physics Group, Department of Applied Physics, University of Granada, 18071 Granada

Abstract

The Calcium Oxalate crystallization is of special interest because of its wide-spread occurrence in biomineralization processes [I-51. The formation of renal stones involves very often the precipitation of calcium oxalates. Calcium oxalate inonohydrate (COM) and calcium oxalate dihydrate (COD) are the crystalline fomls of calcium oxalate (CaOx) most commonly found in kidney stones [S]. Although thermodynamically unstable with respect to the monohydrate the COD is more commonly seen in urine [6].

Published
2015

25. Electrokinetic Analysis of the Influence of Additives on Calcium Oxalate Crystallization

Author

Callejas, J., Martinez, R., De Las Nieves, F. J., Hidalgo-Alvarez, R., Callejas, J., Martinez, R., De Las Nieves, F. J., and Hidalgo-Alvarez, R.

Abstract

The Calcium Oxalate crystallization is of special interest because of its wide-spread occurrence in biomineralization processes [I-51. The formation of renal stones involves very often the precipitation of calcium oxalates. Calcium oxalate inonohydrate (COM) and calcium oxalate dihydrate (COD) are the crystalline fomls of calcium oxalate (CaOx) most commonly found in kidney stones [S]. Although thermodynamically unstable with respect to the monohydrate the COD is more commonly seen in urine [6].

Published
2015

29. Study of association ofCTLA4gene variants to non-anterior uveitis

Author

Leon Rodriguez, D. A., primary, Serrano Lopera, A., additional, Cordero-Coma, M., additional, Márquez, A., additional, Fonollosa, A., additional, Ruiz-Arruza, I., additional, Callejas, J. L., additional, García Serrano, J. L., additional, Díaz Valle, D., additional, Pato, E., additional, Cañal, J., additional, del Rio, M. J., additional, Capella, M. J., additional, Blanco, A., additional, Olea, J. L., additional, Cordero, Y., additional, Martín-Villa, J. M., additional, Gorroño-Echebarría, M. B., additional, Molins, B., additional, Adán, A., additional, and Martin, J., additional

Published
2015
Full Text
View/download PDF

32. Diagnóstico florístico de la ficología marina bentónica en Chiapas

Author

Kurt M. Dreckmann, Abel Sentíes G., Francisco F. Pedroche, and Mariana Callejas J.

Subjects
Pacífico mexicano, Biología, Macroalgas bentónicas, ficoflora estuarina, afinidades florísticas, Chiapas
Abstract

El inventario de macroalgas para 17 localidades en el litoral de Chiapas se compone de 53 especies, incluyendo 16 Chlorophyta , 8 Phaeophyta y 29 Rhodophyta. De las 53 especies, 32 crecen en ambientes estuarinos. Las afinidades florísticas de los estuarios chiapanecos con aquellos del sur del Golfo de México y norte de Quintana Roo, junto al registro fósil, sugieren un contacto marino durante los períodos Eoceno y Mioceno. La presencia de dos macroalgas rojas (una de ellas aún no bien clasificada) en el bentos profundo frente a Chiapas confirma biológicamente la surgencia detectada por la oceanografía física y química. Las afinidades florísticas (Chlorophyta) de Chiapas con los estados de Oaxaca, Michoacán, Colima, Jalisco, Nayarit y Sinaloa, plantean la caracterización de una zona de intercambio de elementos templados y tropicales, para lo cual proponemos el concepto de “Mosaico Ficoflorístico”. Se revisa la posibilidad de integrar la teoría de biogeografía de islas para los estudios de macroalgas estuarinas.

Published
2006

33. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort

Author

Namjou, B., Kothari, P. H., Kelly, J. A., Glenn, S. B., Ojwang, J. O., Adler, A., Alarcon-Riquelme, Marta E., Gallant, Caroline J., Boackle, S. A., Criswell, L. A., Kimberly, R. P., Brown, E., Edberg, J., Stevens, A. M., Jacob, C. O., Tsao, B. P., Gilkeson, G. S., Kamen, D. L., Merrill, J. T., Petri, M., Goldman, R. R., Vila, L. M., Anaya, J-M, Niewold, T. B., Martin, J., Pons-Estel, B. A., Sabio, J. M., Callejas, J. L., Vyse, T. J., Bae, S-C, Perrino, F. W., Freedman, B. I., Scofield, R. H., Moser, K. L., Gaffney, P. M., James, J. A., Langefeld, C. D., Kaufman, K. M., Harley, J. B., Atkinson, J. P., Namjou, B., Kothari, P. H., Kelly, J. A., Glenn, S. B., Ojwang, J. O., Adler, A., Alarcon-Riquelme, Marta E., Gallant, Caroline J., Boackle, S. A., Criswell, L. A., Kimberly, R. P., Brown, E., Edberg, J., Stevens, A. M., Jacob, C. O., Tsao, B. P., Gilkeson, G. S., Kamen, D. L., Merrill, J. T., Petri, M., Goldman, R. R., Vila, L. M., Anaya, J-M, Niewold, T. B., Martin, J., Pons-Estel, B. A., Sabio, J. M., Callejas, J. L., Vyse, T. J., Bae, S-C, Perrino, F. W., Freedman, B. I., Scofield, R. H., Moser, K. L., Gaffney, P. M., James, J. A., Langefeld, C. D., Kaufman, K. M., Harley, J. B., and Atkinson, J. P.

Abstract

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disorder with a complex pathogenesis in which genetic, hormonal and environmental factors have a role. Rare mutations in the TREX1 gene, the major mammalian 3'-5' exonuclease, have been reported in sporadic SLE cases. Some of these mutations have also been identified in a rare pediatric neurological condition featuring an inflammatory encephalopathy known as Aicardi-Goutieres syndrome (AGS). We sought to investigate the frequency of these mutations in a large multi-ancestral cohort of SLE cases and controls. A total of 40 single-nucleotide polymorphisms (SNPs), including both common and rare variants, across the TREX1 gene, were evaluated in similar to 8370 patients with SLE and similar to 7490 control subjects. Stringent quality control procedures were applied, and principal components and admixture proportions were calculated to identify outliers for removal from analysis. Population-based case-control association analyses were performed. P-values, false-discovery rate q values, and odds ratios (OR) with 95% confidence intervals (CI) were calculated. The estimated frequency of TREX1 mutations in our lupus cohort was 0.5%. Five heterozygous mutations were detected at the Y305C polymorphism in European lupus cases but none were observed in European controls. Five African cases incurred heterozygous mutations at the E266G polymorphism and, again, none were observed in the African controls. A rare homozygous R114H mutation was identified in one Asian SLE patient, whereas all genotypes at this mutation in previous reports for SLE were heterozygous. Analysis of common TREX1 SNPs (minor allele frequency (MAF)>10%) revealed a relatively common risk haplotype in European SLE patients with neurological manifestations, especially seizures, with a frequency of 58% in lupus cases compared with 45% in normal controls (P = 0.0008, OR = 1.73, 95% CI = 1.25-2.39). Finally, the presence or absence of specific autoanti

Published
2011
Full Text
View/download PDF

34. The effect of different thawing methods, growth factor combinations and media on the ex vivo expansion of umbilical cord blood primitive and committed progenitors

Author

Anna Rita Migliaccio, Rüdiger V. Sorg, Johannes C. Fischer, Callejas J, Gesine Kögler, and Peter Wernet

Subjects
Adult, CD34, Biology, In Vitro Techniques, Blood cell, Andrology, Colony-Forming Units Assay, Tissue culture, medicine, Humans, Progenitor cell, Growth Substances, Cryopreservation, Transplantation, Hematopoietic Stem Cell Transplantation, Hematology, Fetal Blood, Hematopoietic Stem Cells, Culture Media, Haematopoiesis, Kinetics, medicine.anatomical_structure, Cord blood, Immunology, Ex vivo, Cell Division
Abstract

Assuming a threshold of 2 x 10(7) nucleated cells (NC)/kg body weight required for transplantation and 10 +/- 5 x 10(8) NC per cord blood (CB) unit (n = 1828, July 1997), 100%, 65% and 25% of the CB units stored in the CB Bank Dusseldorf contain sufficient NC to engraft patients of 10 kg, 35 kg and 50-70 kg, respectively. Thus, there is a potential limitation for the use of CB in adults which, however, may be overcome by ex vivo expansion of cells important in the different phases of engraftment. Therefore, four combinations of SCF, Flt3-L, IL-3, erythropoietin and GM-CSF as well as three media were evaluated for their capacity to amplify hematopoietic progenitors. A prerequisite for expansion was the significantly higher recovery of CD34+ cells, colony-forming cells (CFC) and long-term culture-initiating cells (LTC-IC) by thawing cryopreserved CB units with an isotonic albumin/dextran solution. When CD34+ CB cells were cultured with the four cytokine combinations in H5100 medium, all combinations promoted an expansion of total cells (43 to 356-fold) and CFC (49 to 462-fold) within 7 days, however, early progenitors as defined by mixed-colony formation (CFU-GEMM) were substantially amplified only with SCF, Flt3-L plus IL-3 (94.3 +/- 62.4-fold). H5100 medium or a serum-free medium supplemented with SCF, Flt3-L plus IL-3 were superior to 20% FCS/RPMI-1640 medium in the expansion of all progenitor cell types and were similarly effective in supporting the amplification of total cells, CFC, CFU-GM, BFU-E/CFU-E and LTC-IC (maximum at day 7: 6.7 +/- 3.4-fold and 5.5 +/- 0.5-fold, respectively). However, the serum-free medium promoted a significantly higher expansion of CFU-GEMM (176.9 +/- 81.7-fold) than H5100 medium (83.5 +/- 26.2-fold) at day 7 and only under serum-free conditions, CFU-GEMM were maintained over 14 days in tissue culture. These results demonstrate that committed progenitors as well as the more immature CFU-GEMM and LTC-IC can be substantially amplified at the same time without exhausting the proliferative potential.

Published
1998

37. Linfangioma mediastínico

Author

Godoy, R., primary, López, P., additional, León, P., additional, Callejas, J., additional, Ceballos, J.C., additional, and Núñez, A., additional

Published
2009
Full Text
View/download PDF

39. Study of association of CTLA4 gene variants to non-anterior uveitis.

Author

Leon Rodriguez, D. A., Serrano Lopera, A., Cordero‐Coma, M., Márquez, A., Fonollosa, A., Ruiz‐Arruza, I., Callejas, J. L., García Serrano, J. L., Díaz Valle, D., Pato, E., Cañal, J., del Rio, M. J., Capella, M. J., Blanco, A., Olea, J. L., Cordero, Y., Martín‐Villa, J. M., Gorroño‐Echebarría, M. B., Molins, B., and Adán, A.

Subjects
UVEITIS, CYTOTOXIC T lymphocyte-associated molecule-4, DISEASE susceptibility, GENOTYPES, SINGLE nucleotide polymorphisms, GENETICS, PREVENTION
Abstract

This study was undertaken to investigate the possible genetic association of functional CTLA4 polymorphisms with susceptibility to non-anterior uveitis. Four hundred and seventeen patients with endogenous non-anterior uveitis and 1517 healthy controls of Spanish Caucasian origin were genotyped for the CTLA4 polymorphisms rs733618, rs5742909 and rs231775, using predesigned TaqMan© allele discrimination assays. PLINK software was used for the statistical analyses. No significant associations between the CTLA4 polymorphisms and susceptibility to global non-anterior uveitis were found. It was also the case when the potential association of these genetic variants with the anatomical localization of the disease, such as intermediate, posterior or panuveitis, was assessed. Our results do not support a relevant role of these CTLA4 polymorphisms in the non-anterior uveitis genetic predisposition. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

41. Study of a functional polymorphism in thep53 gene in systemic lupus erythematosus: lack of replication in a Spanish population

Author

Sánchez, E, primary, Sabio, J M, additional, Callejas, J L, additional, de Ramón, E, additional, de Haro, M, additional, Jiménez-Alonso, J, additional, Ortego-Centeno, N, additional, Sánchez-Román, J, additional, González-Gay, M A, additional, López-Nevot, M A, additional, González-Escribano, M F, additional, and Martín, J, additional

Published
2006
Full Text
View/download PDF

45. Study of a functional polymorphism in the p53 gene in systemic lupus erythematosus: lack of replication in a Spanish population.

Author

Sánchez, E., Sabio, J. M., Callejas, J. L., de Ramón, E., de Haro, M., Jiménez-Alonso, J., Ortego-Centeno, N., Sánchez-Román, J., González-Gay, M. A., López-Nevot, M. A., González-Escribano, M. F., and Martín, Javier

Subjects
P53 antioncogene, SYSTEMIC lupus erythematosus, AUTOIMMUNE diseases, GENETIC polymorphisms, DISEASE susceptibility, SENSITIVITY (Personality trait)
Abstract

The aim of this study was to assess the possible association between the p53 suppressor gene codon 72 polymorphism and systemic lupus erythematosus (SLE). Our study population consisted of 513 SLE patients and 567 healthy controls. All the individuals were of Spanish Caucasian origin. Genotyping of the p53 codon 72 polymorphism was performed by allele-specific PCR. No statistically significant differences were observed between SLE patients and healthy controls when p53 codon 72 genotype and allele frequencies were compared. In addition, no evidence for association with clinical subfeatures of SLE was found. In conclusion, the p53 codon 72 polymorphism associated with SLE in a Korean population does not appear to play a major role in the susceptibility or severity of SLE in the Spanish population. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

46. Dicella julianii

Author

Ricardo Callejas, J. Betancur, F.J. Roldán, Ricardo Callejas, J. Betancur, F.J. Roldán, Ricardo Callejas, J. Betancur, F.J. Roldán, and Ricardo Callejas, J. Betancur, F.J. Roldán

Abstract

Angiosperms, http://name.umdl.umich.edu/IC-HERB00IC-X-1518082%5DMICH-V-1518082, https://quod.lib.umich.edu/cgi/i/image/api/thumb/herb00ic/1518082/MICH-V-1518082/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. Some materials may be protected by copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, please contact the Herbarium professional staff: herb-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu., https://www.lib.umich.edu/about-us/policies/copyright-policy

Published
1987

47. Mascagnia allopterys

Author

R. Callejas, J. Betancur, F.J. Roldán, C. Martinez, R. Callejas, J. Betancur, F.J. Roldán, C. Martinez, R. Callejas, J. Betancur, F.J. Roldán, C. Martinez, and R. Callejas, J. Betancur, F.J. Roldán, C. Martinez

Abstract

Angiosperms, http://name.umdl.umich.edu/IC-HERB00IC-X-1522206%5DMICH-V-1522206, https://quod.lib.umich.edu/cgi/i/image/api/thumb/herb00ic/1522206/MICH-V-1522206/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. Some materials may be protected by copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, please contact the Herbarium professional staff: herb-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu., https://www.lib.umich.edu/about-us/policies/copyright-policy

Published
1987

48. Pterandra colombiana

Author

R. Callejas & J. Betancur & F.J. Roldán, R. Callejas & J. Betancur & F.J. Roldán, R. Callejas & J. Betancur & F.J. Roldán, and R. Callejas & J. Betancur & F.J. Roldán

Abstract

Angiosperms, http://name.umdl.umich.edu/IC-HERB00IC-X-1102269%5DMICH-V-1102269, https://quod.lib.umich.edu/cgi/i/image/api/thumb/herb00ic/1102269/MICH-V-1102269/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. Some materials may be protected by copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, please contact the Herbarium professional staff: herb-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu., https://www.lib.umich.edu/about-us/policies/copyright-policy

Published
1987

49. Stigmaphyllon herbaceum

Author

Ricardo Callejas, J. Betancur, F. J. Roldán, Ricardo Callejas, J. Betancur, F. J. Roldán, Ricardo Callejas, J. Betancur, F. J. Roldán, and Ricardo Callejas, J. Betancur, F. J. Roldán

Abstract

Angiosperms, http://name.umdl.umich.edu/IC-HERB00IC-X-1525393%5DMICH-V-1525393, https://quod.lib.umich.edu/cgi/i/image/api/thumb/herb00ic/1525393/MICH-V-1525393/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. Some materials may be protected by copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, please contact the Herbarium professional staff: herb-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu., https://www.lib.umich.edu/about-us/policies/copyright-policy

Published
1987

50. Stigmaphyllon herbaceum

Author

R. Callejas, J. Betancur, F. J. Roldán, R. Callejas, J. Betancur, F. J. Roldán, R. Callejas, J. Betancur, F. J. Roldán, and R. Callejas, J. Betancur, F. J. Roldán

Abstract

Angiosperms, http://name.umdl.umich.edu/IC-HERB00IC-X-1525392%5DMICH-V-1525392, https://quod.lib.umich.edu/cgi/i/image/api/thumb/herb00ic/1525392/MICH-V-1525392/!250,250, The University of Michigan Library provides access to these materials for educational and research purposes. Some materials may be protected by copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, please contact the Herbarium professional staff: herb-dlps-help@umich.edu. If you have concerns about the inclusion of an item in this collection, please contact Library Information Technology: libraryit-info@umich.edu., https://www.lib.umich.edu/about-us/policies/copyright-policy

Published
1987

Catalog

Books, media, physical & digital resources
See catalog results